A Nationwide Study on the Incidence of Breast Cancer in Korean Women with Osteoporosis Receiving Raloxifene Treatment

PURPOSE: Raloxifene is a selective estrogen receptor modulator (SERM), and raloxifene treatment for osteoporosis is reimbursable under the Korean National Health Insurance. Evidence suggests that SERMs use reduces the risk of breast cancer in Asian population. Herein, we retrospectively investigated...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Jihyoun, Lee, Ji Sung, Lee, Jong Eun, Kim, Zisun, Han, Sun Wook, Hur, Sung Mo, Choi, Young Jin, Park, Sungmin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Breast Cancer Society 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8250100/
https://www.ncbi.nlm.nih.gov/pubmed/34128366
http://dx.doi.org/10.4048/jbc.2021.24.e28

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8250100/
https://www.ncbi.nlm.nih.gov/pubmed/34128366
http://dx.doi.org/10.4048/jbc.2021.24.e28

Ejemplares similares